Introduction
Autosomal recessive cerebellar ataxias (ARCAs) are a clinically and genetically heterogeneous group of spinocerebellar diseases, often associated with additional non-cerebellar features (Fogel and Perlman, 2007; Anheim et al., 2012) . Two clinically defined syndromes combine early-onset ARCA with hypogonadotropic hypogonadism: (i) Boucher-Neuhä user syndrome (MIM 215470), which is additionally associated with chorioretinal dystrophy (Boucher and Gibberd, 1969; Neuhauser and Opitz, 1975; Limber et al., 1989) ; and (ii) Gordon Holmes syndrome (MIM 212840), which is additionally associated with brisk reflexes (Holmes, 1907) . Despite various descriptions of familial occurrence, the genetic basis of these syndromes has remained elusive. Moreover, it has remained unclear whether these syndromes present clinically and genetically distinct entities or, alternatively, phenotypic clusters on a phenotypic continuum of neurodegenerative diseases caused by mutations in the same gene.
Here we demonstrate that Boucher-Neuhä user and Gordon Holmes syndromes are indeed allelic diseases and reveal the major disease gene for these clinical disease entities. By using the significant genetic variants identified in Boucher-Neuhä user and Gordon Holmes syndrome families as a seed we also analysed 4500 exomes from patients with hereditary ataxia and/or spasticity syndromes and establish that variants in the new Boucher-Neuhä user syndrome/ Gordon Holmes syndrome disease gene are not specific to these particular hypogonadism syndromes, but rather cause these presentations as part of a wider spectrum of neurodegenerative disease.
Materials and methods
Whole exome sequencing of index patients with Boucher-Neuhä user syndrome and Gordon Holmes syndrome
Whole exome sequencing was performed on two index patients with familial Boucher-Neuhä user syndrome and one index patient with sporadic Gordon Holmes syndrome. Informed consent was obtained from all individuals and the Institutional Review Boards of the participating medical centres approved the study. The SureSelect Human All Exon 50 Mb kit (Agilent) was used for in-solution enrichment and exome sequencing was performed using the HiSeq2000 instrument (Illumina). Paired-end reads of 100-bp length were produced. BWA and GATK software packages (Li and Durbin, 2009; McKenna et al., 2010; DePristo et al., 2011) were used to align sequence reads to the reference and call variant positions, respectively. All data were then annotated and imported into GEnomes Management Application (GEM.app), a web-based tool for next generation sequencing data analysis (genomics.med.miami.edu). An average of 73 609 687 sequence reads was produced per sample, 98.8% of which could be aligned to the targeted sequence. Mean coverage was 69-fold; 71% of the targeted sequence was covered by at least 20 reads.
Assuming a common cause for Boucher-Neuhä user and Gordon Holmes syndromes, we used the GEM.app analysis module 'Genes Across Families' to filter for non-synonymous homozygous or compound heterozygous variants, with low frequency in public databases (minor allele frequency in dbSNP137 and NHLBI ESP6500 5 0.5%), moderate conservation (GERP score 4 2 OR PhastCons score 4 0.6) and moderate genotype quality (GATK quality index 4 30 and genotype quality GQ 4 30) in genes shared across the three families. Only one gene, PNPLA6 (NCBI reference NM_001166111.1), remained as a candidate gene between the Boucher-Neuhä user and Gordon Holmes syndrome index patients with segregating variants that were conserved, rare, and predicted to be damaging by at least three different in silico algorithms (MutationTaster; MutationAssesor; Likelihood Ratio Test; and PolyPhen2).
Sanger sequencing of the candidate gene in additional Boucher-Neuhä user syndrome families
To confirm the significance of PNPLA6 mutations in the pathogenesis of ataxia-hypogonadism syndromes, we screened the PNPLA6 gene in index patients from four additional Boucher-Neuhä user syndrome families by conventional Sanger sequencing. Oligonucleotide sequences are available upon request.
PNPLA6 seed analysis in more than 500 exomes of index patients with ataxia, hereditary spastic paraplegia and Charcot-Marie-Tooth disease
To explore the possibility that Boucher-Neuhä user and Gordon Holmes syndromes are clusters on a wide spectrum of neurodegenerative disease, PNPLA6 was used as a seed in the analysis of exome data from 538 unrelated patients with the following non-Boucher-Neuhä user syndrome/Gordon Holmes syndrome neurodegenerative diseases: nonBoucher-Neuhä user syndrome/Gordon Holmes syndrome early-onset ataxia (age of onset 530 years) (n = 67), non-Boucher-Neuhä user syndrome/Gordon Holmes syndrome complex hereditary spastic paraplegia (n = 144), pure hereditary spastic paraplegia (n = 192) and CharcotMarie-Tooth disease (CMT) type 2 compatible with recessive disease (CMT2; n = 135). In addition, we screened for PNPLA6 mutations in 1637 additional whole exomes from a wide range of (non-ataxia, nonhereditary spastic paraplegia, non-CMT2) neurological phenotypes. The latter were used as a control cohort to scrutinize the possibility that recessive mutations observed in our target cohort are just a result of genetic variability of the PNPLA6 gene with common occurrence of unique or rare variants not related to the disease.
Structural models of wild-type and mutant PNPLA6 domains
Structural models of various wild-type and mutant domains of human PNPLA6 (UniProt# Q8IY17-4) were built using the MODELLER software based on homology modelling (Marti-Renom et al., 2000) . Briefly, the structural model of wild-type phospholipid esterase domain (EST), which represents the site of location of Ser1045Leu, Thr1058Ile, Phe1066Ser, Val1100Gly, Val1110Met and Pro1122Leu mutations, was constructed using the crystal structure of the homologous EST catalytic domain of the plant patatin PAT17 (PDB# 1OXW) (Rydel et al., 2003) . The structural models of various wild-type and mutant CNB1/2 domains in complex with cyclic adenine monophosphate were obtained using the crystal structure of the homologous CNB2 domain of the regulatory alpha-subunit of cyclic adenine monophosphate-dependent protein kinase A bound to cyclic adenine monophosphate (PDB# 1RGS) (Su et al., 1995) . In each case, a total of 100 atomic models were calculated and the structures with the lowest energies, as judged by the MODELLER Objective Function, were selected for further analysis. The atomic models were rendered using RIBBONS (Carson, 1991) .
Clinical assessment
All index patients carrying two pathogenic PNPLA6 variants as well as their affected siblings received a systematic clinical assessment for disturbances in multiple neurological systems (Table 1) . In all subjects, routine MRI was performed.
Results

PNPLA6 causes Boucher-Neuhä user syndrome and Gordon Holmes syndrome
By intersecting the identified variants in whole exomes from two index patients with Boucher-Neuhä user syndrome and one index patient with Gordon Holmes syndrome under recessive inheritance models, only PNPLA6 remained as a candidate gene. All variants identified in these cases were conserved, had low frequency in the general population, and were predicted to be damaging by at least three different in silico algorithms ( 
PNPLA6 causes a wide spectrum of neurodegenerative disease
To explore the possibility that Boucher-Neuhä user syndrome and Gordon Holmes syndrome are only clusters on a wider spectrum of neurodegenerative disease, PNPLA6 was used as a 'seed' in the analysis of exome data from 538 unrelated patients with non-Boucher-Neuhä user syndrome/Gordon Holmes syndrome neurodegenerative diseases (non-Boucher-Neuhä user syndrome/ Gordon Holmes syndrome early-onset ataxia; non-BoucherNeuhä user syndrome/Gordon Holmes syndrome hereditary spastic paraplegia; CMT type 2) where family history was compatible with recessive disease. This analysis identified a spastic ataxia patient (Subject IHG26117), who carried significant compound heterozygous changes (c. (Table 2) .
In total, we report seven families from five different countries with significant novel mutations in PNPLA6. These variants cosegregated with the disease in all families where family members were available ( Supplementary Fig. 1 ). All affected base pairs are highly conserved across species (Fig. 1B) and were absent or had low minor allele frequency in GEM.app (2175 exomes), dbSNP137, and NHLBI ESP (6500 exomes) (Table 2) . Remarkably, in 1637 additional whole exomes from a wide range of neurological phenotypes no additional homozygous or compound heterozygous changes were present in PNPLA6 under relaxed filter conditions (minor allele frequency in Gem.app, dbSNP137 and NHLBI ESP 6500 exomes 53%, low quality scores, low conservation scores) (Fisher's exact test, two-tailed, P = 0.0001).
Structural in silico protein modelling
The majority of identified PNPLA6 mutations clustered within a short stretch of 5100 residues in the EST domain. This domain has been shown to de-esterify phosphatidylcholine, a major component of biological membranes, into its constituent fatty acids and glycerophosphocholine (Strickland et al., 1995; Atkins et al., 2002; van Tienhoven et al., 2002; Zaccheo et al., 2004) (Fig. 1A) . Glycerophosphocholine serves as a precursor for the biosynthesis of acetylcholine, a key neurotransmitter involved in mediating cellular signalling in the nervous system. On the CNB1-CNB2-CNB3-EST modular architecture of PNPLA6 (Fig. 1A) , we observe that mutations from residues Gly840-Ser1031 associated with spasticity (spastic paraplegia and spastic ataxia) largely cluster at the N-terminal side of the EST domain. Towards the C-terminal end of the EST domain, a second mutational cluster between residues Ser1031-Pro1122 causes cerebellar ataxia and/or hypogonadism (Boucher-Neuhä user syndrome, Gordon Holmes syndrome, spastic ataxia). Next, we built structural models of CNB1/2 and EST domains using the crystal structures of the homologous CNB2 domain of the regulatory alpha-subunit of cyclic adenine monophosphate-dependent protein kinase A bound to cyclic adenine monophosphate (Protein Data Bank #1RGS) (Su et al., 1995) and the homologous EST catalytic domain of the plant patatin PAT17 (Protein Data Bank #1OXW) (Rydel et al., 2003) (Fig. 1C ). An extensive description of these studies is provided in Supplementary Figs 3 and 4 . Our structural models reveal that the catalytic centre of the EST domain adopts a funnel-like shape that constitutes the entry route for the phosphatidylcholine substrate, where the active site Ser1014/Asp1144 catalytic dyad is located deep at the base of the funnel. The EST missense mutations may result in misalignment of active site residues Ser1014/Asp1144 so as to compromise its enzymatic function. It is also highly probable that mutations such as Thr1058Ile and Pro1122Leu may block the entry of phosphatidylcholine substrate to the active site residues located deep at the base of the catalytic funnel. Finally, although the highly conserved Val1100Gly mutation is located at a distal site away from the catalytic centre, it may also indirectly affect protein dynamics that could ultimately shut down the enzymatic activity of PNPLA6. Additionally, two changes were located in the CNB1 and 2 domains (p.Val263Ile, p.Gly578Trp) (Fig. 1A) . Our analysis suggests that these two mutations will likely compromise the ability of one or both regulatory CNB1/2 domains to bind cyclic nucleotide-monophosphate binding domains (cNMPs) and their failure to undergo a conformational change in response to changes in intracellular concentration of cNMPs would thus keep the EST domain in an auto-inhibited state ( Supplementary  Fig. 4 ). 
Clinical findings
We aggregated clinical data from 12 affected subjects belonging to seven families. All four index subjects with Boucher-Neuhä user syndrome presented with the classical triad: visual impairment, ataxia and delayed puberty (Fig. 2B-D) . Symptoms in the individuals with Boucher-Neuhä user syndrome started before the age of 8 years and were slowly progressive in all affected individuals with variable progression rates both between and within families, leading to wheelchair-dependency in the most severely affected subjects. In-line with the original publications of Boucher-Neuhä user and Gordon Holmes syndromes (Holmes, 1907; Neuhauser and Opitz, 1975) , two of four subjects with Boucher-Neuhä user syndrome as well as the subject with Gordon Holmes syndrome showed clinical signs of upper motor neuron disease (spasticity, positive extensor plantar reflex and/or brisk reflexes), including a spastic Boucher-Neuhä user syndrome phenotype (Family ARCA_05). Achilles tendon reflexes were reduced or absent in all subjects with Boucher-Neuhä user syndrome, providing clinical evidence that peripheral neuropathy is commonly associated with Boucher-Neuhä user syndrome in our subjects. Neuropathy was of sensorimotor axonal type in those subjects with BoucherNeuhä user syndrome where nerve conduction studies were available. Affected siblings within Boucher-Neuhä user syndrome families showed broadly similar phenotypes and age of onset (Table 1) . However, the initial symptom of disease differed between and within Boucher-Neuhä user syndrome families: whereas disease started with visual impairments in some subjects with Boucher-Neuhä user syndrome, it presented with gait ataxia or delayed puberty in others (Table 1) . Moreover, in BoucherNeuhä user syndrome Family ARCA_05 one of the affected siblings (Subject 2) did not show evidence for chorioretinal dystrophy The side chain moieties of active site residues (Ser1014/Asp1144) and those identified here to be prone to mutations (Ser1045/Thr1058/Phe1066/ Val1100/Val110/Pro1122) are coloured red and blue, respectively. The funnel-shaped catalytic centre of the EST domain-where the active site residues Ser1014/Asp1144 are located deep at the base of the funnel whereas the rim of the funnel represents the entry route for the phosphatidylcholine (PDC)_substrate (green arrow)-is represented by yellow dashed lines. Note that the structural model of EST domain was built using the crystal structure of the homologous EST catalytic domain of the plant patatin PAT17 (PDB# 1OXW) (Rydel et al., 2003) in MODELLER (Marti-Renom et al., 2000) . A total of 100 atomic models were calculated and the structure with the lowest energy, as judged by the MODELLER Objective Function, was selected for further analysis. The structural model was rendered using RIBBONS (Carson, 1991) (for a larger version and an additional rotation perspective, see Supplementary Fig. 3 ).
indicating this as a non-obligate feature. This is further supported by the findings that the cases with hereditary spastic paraplegia and spastic ataxia showed neither retinal dystrophy nor hypogonadism (Table 1) , thus demonstrating that hypogonadism is not an obligate feature of disease. Disease in the cases with hereditary spastic paraplegia and spastic ataxia also started before the age of 20 years, corroborating the notion that early-onset neurodegeneration is a common denominator across all affected subjects.
Discussion
To date, the genetic basis of Boucher-Neuhä user and Gordon Holmes syndromes has not been identified. Here we use exome sequencing to uncover the genetic cause of these two clinical entities and demonstrate that they are allelic diseases, both caused by recessive PNPLA6 mutations. PNPLA6 seems to be a major cause of Boucher-Neuhä user syndrome with four of six Boucher-Neuhä user syndrome families carrying PNPLA6 mutations. As not all subjects with Boucher-Neuhä user syndrome carried PNPLA6 mutations, the genetic basis of Boucher-Neuhä user syndrome might either be heterogeneous or caused by PNPLA6 mutations not detected by routine sequencing procedures (e.g. deletions or intronic mutations). Further heterogeneity of ataxiahypogonadism syndromes is also supported by the recent observation that mutations in RNF216 and the combination of mutations in RNF216 and OTUD4 (Margolin et al., 2013) cause ataxiahypogonadism syndromes complicated by dementia. In contrast to RNF216/OTUD4-associated ataxia-hypogonadism, BoucherNeuhä user syndrome and Gordon Holmes syndrome are not typically accompanied by dementia. The clinical spectrum of PNPLA6 mutations unfolds along four different neurological key features: ataxia, chorioretinal dystrophy, hypogonadotropic hypogonadism and motor neuron disease (upper motor neuron disease with or without additional lower motor neuropathy). Accordingly, Boucher-Neuhä user syndrome (BNS) and Gordon Holmes syndrome (GHS) are not distinct entities, but clusters on a continuous spectrum of PNPLA6-associated disease, extending from Boucher-Neuhä user syndrome via Gordon Holmes syndrome to spastic ataxia (sATX) and pure hereditary spastic paraplegia (HSP). The phenotype of complicated hereditary spastic paraplegia, which has been considered the most prominent phenotype of PNPLA6 so far (Rainier et al., 2008) , is only the 'tip of the iceberg' of this broad disease spectrum. (B) Photograph of the full body of a male patient with Boucher-Neuhä user syndrome (Subject IHG 25357) at age 26 years illustrating incomplete secondary sex characteristics with lack of body hair and gynecomastia. (C) Exemplary fundus photography of the Boucher-Neuhä user syndrome Patient ARCA_05 showing chorioretinal degeneration, characterized by diffuse atrophy of choroidal vessels and the retinal pigment epithelium with pigment clumps. The optic nerve shows no signs of atrophy. (D) Sagittal T 2 -weighted MRI of this subject with Boucher-Neuhä user syndrome shows marked cerebellar atrophy.
